These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15485306)

  • 1. The ODAC chronicles: part 1. My first ODAC experience.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):709-12. PubMed ID: 15485306
    [No Abstract]   [Full Text] [Related]  

  • 2. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 3. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 4. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
    [No Abstract]   [Full Text] [Related]  

  • 5. The ODAC chronicles: Part 5. Prostate cancer endpoints.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):405-10. PubMed ID: 16001947
    [No Abstract]   [Full Text] [Related]  

  • 6. The ODAC Chronicles: part 7. Tale of two goals.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):939-41. PubMed ID: 16336083
    [No Abstract]   [Full Text] [Related]  

  • 7. The ODAC Chronicles: Part 6a. ODAC's structure and function.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):573-7. PubMed ID: 16111457
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 10. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 11. The ODAC Chronicles: part 6b. ODAC's structure and function.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):753-6. PubMed ID: 16221044
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient group seeks overhaul of FDA clinical trial system in court.
    Hede K
    J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 17. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of effective new treatments for multiple myeloma.
    Anderson KC; Pazdur R; Farrell AT
    J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064
    [No Abstract]   [Full Text] [Related]  

  • 20. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.